Sign in
Taking peoplePhase 3

FocaL Mass Drug Administration for Vivax Malaria Elimination

Key facts

Who runs it
University of California, San Francisco
Where
Peru1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
7,530 people, planned
Started
14 Oct 2024
Expected to end
1 May 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Focal Mass Drug Administration (fMDA)
Record updated
9 June 2026

Who can take part

Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Cluster eligibility; Within 8 hours transport of Iquitos; Incidence <250/1000 and >2 cases year prior to trial; Population size (<650)
  • Chloroquine (CQ) eligibility; Resides in neighboring household but within 200 m of Pv index case in the past 2 years; Age ≥6 months old; Present for intervention; Adult ≥18 years old that provides informed consent; A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents; A child ≥6 months old and <8 years old that has informed consent from their parents
  • Tafenoquine (TQ) eligibility; Eligible to receive CQ; Age ≥16 years old; Adult ≥18 years old that provides informed consent; A child ≥16 years and <18 years old that provides informed assent and has informed consent from their parents
  • Primaquine eligibility; Eligible to receive CQ and ineligible to receive TQ; Age ≥6 months old; Adult ≥18 years old that provides informed consent; A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents; A child ≥6 months old and <8 years old that has informed consent from their parents
  • Baseline evaluation and informed consent; -Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks
  • Eligibility for fMDA; High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle; Villagers that were eligible but missed in the 1st round in a cycle, or become eligible in the next two months, will not be eligible to receive fMDA in the 2nd round in a cycle

Who cannot take part

  • Chloroquine eligibility; History of retinal or visual field changes; Known hypersensitivity or adverse reaction to CQ; Currently taking CQ or have taken CQ in the past four weeks; Ineligible for TQ or PQ (see criteria below); Hemoglobin <9 g/dL
  • Tafenoquine eligibility; G6PD deficiency or intermediate status (defined as activity ≤6.0 UI/gHb per SD biosensor); G6PD status unknown or refusal of G6PD status test; Acute or severe malaria; Pregnancy (known or identified by pregnancy test); Refusal of pregnancy test if new amenorrhea in the past 4 weeks; Woman breastfeeding a child that is G6PD deficient or with unknown G6PD status; Known hypersensitivity or adverse reaction to TQ or PQ; Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks; Hemoglobin < 9 g/dL
  • Primaquine eligibility; G6PD deficiency (defined as activity ≤4.0 UI/gHb per SD biosensor); G6PD status unknown or refusal of G6PD status test; Acute or severe malaria; Pregnancy (known or identified by pregnancy test); Refusal of pregnancy test if new amenorrhea in the past 4 weeks; Breastfeeding child with documented or unknown G6PD deficiency status; Woman breastfeeding a child with documented or unknown G6PD deficiency status; Known hypersensitivity or adverse reaction to TQ or PQ; Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks; Hemoglobin < 9 g/dL

This trial is currently available in Peru.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.

The 2 groups in the trial

  • Control: Standard InterventionsNo study treatment, for comparison

    Standard interventions for the control cluster will include providing participants with long-lasting insecticide-treated bednets, management of known and possible mosquito breeding sites, passive case detection through detection and diagnosis of symptomatic cases of malaria in health facilities and through community health workers (conducted in villagers with fever), microscopy testing in households of recent index cases to detect asymptomatic malaria cases, and treatment of active cases of malaria (artesunate-mefloquine (AS-MQ) for Plasmodium falciparum and Chloroquine (CQ) (10 mg/kg on days 1 and 2, followed by 5 mg/kg on day 3) + PQ (0.5mg/kg x 7 days).

  • Focal Mass Drug Administration (fMDA)Treatment being tested

    Standard interventions in addition to focal mass drug administration. Focal mass drug administration will include using primaquine, chloroquine, and tafenoquine, for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax (Pv) index case households from the prior 2 years (including individuals in the index case household). Pv index cases include symptomatic cases detected at health facilities or in fever screenings, and asymptomatic cases identified during routine active case detection by health facilities. Households will then be notified regarding their potential to receive two rounds fMDA that cycle. Eligibility to receive medications as part of fMDA will be assessed prior to each administration and include glucose 6 phosphate dehydrogenase (G6PD) testing and counseling if not previously conducted or result is not available on the participant's identification card.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru
Publications
Record updated
9 June 2026